ELCO Management Co. LLC continued to hold its position in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,126 shares of the company’s stock at the close of the second quarter. ELCO Management Co. LLC’s holdings in Taro Pharmaceutical Industries were worth $238,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. FMR LLC boosted its position in Taro Pharmaceutical Industries by 42.2% during the second quarter. FMR LLC now owns 466,590 shares of the company’s stock valued at $52,286,000 after purchasing an additional 138,353 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Taro Pharmaceutical Industries by 35.3% during the second quarter. Dimensional Fund Advisors LP now owns 178,392 shares of the company’s stock valued at $19,991,000 after purchasing an additional 46,570 shares during the last quarter. River Road Asset Management LLC boosted its position in Taro Pharmaceutical Industries by 33.3% during the second quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock valued at $7,337,000 after purchasing an additional 16,350 shares during the last quarter. Aperio Group LLC boosted its position in Taro Pharmaceutical Industries by 46.9% during the second quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock valued at $5,696,000 after purchasing an additional 16,233 shares during the last quarter. Finally, AHL Partners LLP boosted its position in Taro Pharmaceutical Industries by 35.2% during the second quarter. AHL Partners LLP now owns 26,604 shares of the company’s stock valued at $2,981,000 after purchasing an additional 6,923 shares during the last quarter. Institutional investors and hedge funds own 14.20% of the company’s stock.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE TARO) traded up 0.07% on Thursday, reaching $113.00. The company had a trading volume of 1,971 shares. The stock has a market cap of $4.58 billion, a PE ratio of 11.51 and a beta of 0.65. The stock has a 50-day moving average price of $106.12 and a 200-day moving average price of $111.42. Taro Pharmaceutical Industries Ltd. has a 12 month low of $92.28 and a 12 month high of $124.52.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/taro-pharmaceutical-industries-ltd-taro-holdings-maintained-by-elco-management-co-llc/1610367.html.

TARO has been the subject of several recent research reports. BidaskClub cut Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. TheStreet cut Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a research report on Thursday, June 15th.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.